Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

Heidi J. Gray,Benedict B. Benigno,Jonathan S. Berek,J Chang,James Mason,Linda Mileshkin,Paul Mitchell,M Moradi,F Recio,C M Michener,Angeles Alvarez Secord,N. E. Tchabo,John K. Chan,J Young,Holbrook Kohrt,Sharron Gargosky,Jeffrey C. Goh

Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

2016

Heidi J. Gray
Benedict B. Benigno
Jonathan S. Berek
J Chang
James Mason
Linda Mileshkin
Paul Mitchell
M Moradi
F Recio
C M Michener
Angeles Alvarez Secord
N. E. Tchabo
John K. Chan
J Young
Holbrook Kohrt
Sharron Gargosky
Jeffrey C. Goh

Background CAN-003 was a randomized, open-label, Phase 2 trial evaluating the safety, efficacy and immune outcomes of CVac, a mucin 1 targeted-dendritic cell (DC) treatment as a maintenance therapy to patients with epithelial ovarian cancer (EOC).

Keywords:

Ovarian cancer
Cell
Dendritic Cell Therapy
Immune system
Immunotherapy
Mucin
Maintenance therapy
Oncology
Text mining
Internal medicine
Medicine
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations